| Document |
Document Title |
|
WO/2023/073116A1 |
The present invention concerns a method of generating an immune response to bacteria in a subject, in which live bacteria (such as BCG) and a photosensitizing agent are administered to cells of the subject and the cells are irradiated wi...
|
|
WO/2023/077133A2 |
Provided herein are, inter alia, methods, compositions and kits for treating a hypothalamic-regulated behavior Also included herein are kits for treating a hypothalamic-regulated behavior.
|
|
WO/2023/076701A2 |
Provided herein are methods for one or more of a) modulating an immune response to a tumor cell in a patient, b) treating cancer in a cancer patient; or c) eliciting an anti-tumor response in a patient, comprising modulating the expressi...
|
|
WO/2023/068829A1 |
The present invention relates to a composition comprising iron oxide magnetic particles. The composition can be delivered specifically to hepatocytes to minimize damage to other organs, and is safe as the composition is excreted from the...
|
|
WO/2023/068104A1 |
The present invention provides a medical agent improving antitumor effect.
|
|
WO/2023/067519A1 |
Methods and topical compositions for the treatment of a dermatological disorder are provided. The topical composition includes 5-aminolevulinic acid, at least one penetration enhancer and at least one chelating agent. Further, methods an...
|
|
WO/2023/068325A1 |
Provided is an anticancer agent containing nitrogen 15 and also containing a substance that is accumulated specifically in cancer cells. Also provided is a method for killing cancer cells in vitro, said method comprising accumulating nit...
|
|
WO/2023/066076A1 |
The subject invention pertains to photocleavable prodrugs that facilitate the controllable drug delivery to the target sites modulated by light irradiation, including a photocleavable boron-dipyrromethene-derived prodrug and a dye, which...
|
|
WO/2023/069094A1 |
A method and apparatus for reducing or inactivating pathogens in units of whole blood. A plurality of superparamagnetic nanoparticles (SPN) is coated with a mixture of chemiluminescence light-generating compounds and photodynamic broad-s...
|
|
WO/2023/068423A1 |
The present invention relates to: a core/shell-type anticancer composition comprising a core including a photosensitizer represented by chemical formula 1 and a shell including bovine serum albumin or human serum albumin; and a preparati...
|
|
WO/2023/068828A1 |
The present invention relates to a method for preparing a composition comprising iron oxide magnetic particles, and a composition comprising iron oxide magnetic particles, wherein the composition prepared by the preparation method is del...
|
|
WO/2023/064887A1 |
Provided herein are compositions and methods for mechanochemical dynamic therapy.
|
|
WO/2023/061194A1 |
Disclosed in the present invention are a photosensitizer molecule and the use thereof in the increase of the retention time thereof in a tumor and the enhancement of the therapy for large-volume tumors, which belong to the field of nano-...
|
|
WO/2023/064782A2 |
Methods of treatment, methods of detection, and kits associated with ERα+ cancer, such as ERα+ breast cancer, are disclosed herein. The methods and kits disclosed herein can assist physicians in relieving patient suffering by identifyi...
|
|
WO/2023/059180A1 |
The present invention discloses formulated topical agents comprising a compound pheophorbide a in photosensitizer for use in photodynamic therapy (PDT) particularly in skin disorders, skin lesions, or skin cancer.A topical agent compound...
|
|
WO/2023/060283A2 |
According to various aspects of this disclosure, the present disclosure relates to a method of treating cancer in a subject in need thereof comprising administering to the subject an anti-TROP2 antibody drug conjugate and a therapeutic a...
|
|
WO/2023/056717A1 |
Provided is a preparation method for a functional silk fibroin (SF) drug carrier, comprising: degumming, dissolving, dialyzing, filtering, and concentrating Bombyx mori silkworm silk to obtain an SF dissolving solution; using a cross-lin...
|
|
WO/2023/059621A1 |
In one aspect, compositions and methods are described herein for providing a microenvironment mapping platform operable to selectively identify various features, including in vivo protein-protein interactions on cellular membranes. In so...
|
|
WO/2023/059184A1 |
The invention provides a method for providing a coated nanoparticle material (35), wherein the method comprises (i) a first stage (100), (ii) a second stage (200), and (iii) a coating stage (300), wherein: the first stage (100) comprises...
|
|
WO/2023/060147A1 |
Provided are compositions comprising phthalocyanine (PC)-loaded or naphthalocyanine (NC) dye-loaded nanoparticulate polymeric or lipid micelles and methods for visualization of tumors without optical imaging equipment, the methods compri...
|
|
WO/2023/051796A1 |
Disclosed in the present invention are a production system and method for producing nanoparticles. Particularly disclosed is a production system, the production system comprising (1) a first pipeline, (2) a second pipeline, (3) a combine...
|
|
WO/2023/055129A1 |
The present invention relates to a pharmaceutical composition comprising magnetic nanoparticle-bearing mesenchymal stem cells for preventing or treating nerve diseases and the use thereof. When migrated and engrafted to a target site by ...
|
|
WO/2023/055885A2 |
Described herein are methods for preventing or treating KRAS mutant pancreatic cancer in a subject in need thereof comprising administering to the subject an effective amount of (i) an effective amount of a PRC2 inhibitor, (ii) an effect...
|
|
WO/2023/055641A2 |
Described herein are methods and compositions for treating cancer. Aspects of the invention relate to administering to a subject having cancer an inhibitor of the super elongation complex (SEC). In various embodiments, the cancer is a bl...
|
|
WO/2023/048231A1 |
The problem of the present invention is to provide a medicine for killing tumor cells, said medicine having few side effects. The present invention provides a medicine for killing tumor cells, said medicine containing: a conjugate of a s...
|
|
WO/2023/048233A1 |
The present invention addresses the problem of providing a medicine that is for killing tumor cells, and that has few side effects. The present invention provides: a conjugate between a cytotoxin and a substance that binds with a target ...
|
|
WO/2023/049262A1 |
Compositions and methods for treating cutaneous radiation injury (CRI), including radiation dermatitis, radiation proctopathy, or oral mucositis, employing one or more functional inhibitor of acid sphingomyelinase (FIASMA).
|
|
WO/2023/046709A1 |
The present invention relates to inactivated stem cells, which can be stored for several days in a refrigerator (above 0°C, preferably in the range 0.1-10°C) and still maintain their cellular and phenotypic integrity as well as therape...
|
|
WO/2023/044436A1 |
Amorphous nanoparticle compositions comprising a photosensitizer along with methods of making and using the same are provided. In particular, the amorphous nanoparticle compositions are generated and used in carrier-free, solubilizing ag...
|
|
WO/2023/041938A1 |
The invention provides endoplasmic reticulum-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acce...
|
|
WO/2023/039226A2 |
Therapeutics and methods treating Alzheimer's disease or a pre- Alzheimer's disease condition in a patient comprising administering a pharmaceutical composition containing a therapeutically effective dose therapeutic, wherein the therape...
|
|
WO/2023/039175A2 |
The present invention provides methods for treating or selecting a subject for treatment of a retinal disease or disorder, including, without limitation, achromatopsia (ACHM), based on an analysis of the subject's retinal structure and/o...
|
|
WO/2023/035460A1 |
A composite photothermal material, a preparation method therefor and the use thereof. The composite photothermal material comprises a two-dimensional photothermal material matrix. The two-dimensional photothermal material matrix is two-d...
|
|
WO/2023/036878A1 |
The present invention refers to novel UV-light cleavable drug conjugates comprising a diazirine linker.
|
|
WO/2023/037311A1 |
Here polymeric nanoparticle formulations based on the combination of 3 monomers were identified lead candidates capable of efficient mRNA delivery, after evaluating 152 formulations by high-throughput screening using a reporter fibroblas...
|
|
WO/2023/038968A2 |
Compositions and methods are disclosed for treating a skin condition in a mammal in need thereof by administering to the affected tissues a therapeutically effective amount of a composition comprising a bacterial ceramidase inhibitor and...
|
|
WO/2023/038368A1 |
The present invention relates to anticancer therapy using adenosine diphosphate ribose (ADP-ribose) and, more particularly, to ADP-ribose as a sole anticancer therapy and combination therapy with anticancer drugs and radiation.
|
|
WO/2023/034461A1 |
A method of treating pancreatic cancer comprising: contacting a pancreatic cancer to be treated with a plasmonic photothermal agent forming a sensitized target; and exposing the sensitized target to light having a resonance wavelength of...
|
|
WO/2023/034963A2 |
Provided herein are uses of antibodies that bind to CD163 expressed on a human myeloid cell in combination with checkpoint inhibitors. Among other things, these CD163 antibodies can be used with checkpoint inhibitors in methods of treatm...
|
|
WO/2023/028656A1 |
The present disclosure relates to magnetic nanoparticles having a core-multishell structure comprising at least two shells, and methods for their preparation.
|
|
WO/2023/029935A1 |
The present application relates to a boron carrying agent for integrated tumor diagnosis and treatment, a preparation method therefor and a use thereof. Provided is a compound represented by formula I, wherein an R group is hydrogen or a...
|
|
WO/2023/034914A2 |
This disclosure provides methods and compositions for preventing and treating synucleinopathies.
|
|
WO/2023/028508A2 |
The present disclosure relates to inhibitors of the MYC:TRRAP interaction and their use in the prevention or treatment of cancer and disclosed. Disclosed compounds include 3,9-Dihydroxy-4-prenyl-[6aR;11aR]pterocarpan, N-[4-(diethylamino)...
|
|
WO/2023/026791A1 |
The purpose of the present invention is to provide a detecting agent (diagnostic agent) and a treatment agent that are taken into tumors in vivo promptly and that bind to c-KIT target molecules. In the quest for a molecular species that ...
|
|
WO/2023/027460A1 |
A sonosensitive polymersome formulation according to the present invention, which is based on an amphipathic copolymer, is characterized by high load efficiency for a sonosensitizer and an anticancer agent as well as by effective payload...
|
|
WO/2023/023587A2 |
Methods, compositions and kits for enhancing immune cell mediated cancer treatment in overweight and obese individuals.
|
|
WO/2023/021024A1 |
The present invention relates to the treatment of cancer by administering thermosensitive liposomes comprising doxorubicin. The liposome administration may preferably be combined with hyperthermia before, during and/or after the liposome...
|
|
WO/2023/023538A2 |
This document provides methods and materials involved in treating mammals (e.g., humans) having tissue inflammation (e.g., autoimmune tissue inflammation). For example, one or more inhibitors of production of a tumor necrosis factor-α (...
|
|
WO/2023/023189A2 |
Provided are methods for treating Alzheimer's Disease and/or ameliorating at least one symptom thereof. In some embodiments, the methods include administering to a. subject with AD an inhibitor of a clusterin biological activity, wherein...
|
|
WO/2023/022623A1 |
The invention relates to the chemistry of biologically active compounds, and more particularly to an agent containing a derivative of a series of natural porphyrins of formula (1) and lipids for forming a liposomal form or an emulsion. T...
|
